Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR

被引:1
|
作者
Muniz-Saenz-Diez, Javier [1 ]
Ezponda, Ana [2 ]
Caballeros, Meylin [3 ]
de la Fuente, Ana [4 ]
Gavira, Juan J. [1 ]
Bastarrika, Gorka [2 ]
机构
[1] Clin Univ Navarra, Dept Cardiol, Ave Pio XII 36, Pamplona 31007, Spain
[2] Clin Univ Navarra, Dept Radiol, Pamplona, Spain
[3] Clin Univ Navarra, Dept Radiol, Madrid, Spain
[4] Clin Univ Navarra, Dept Cardiol, Madrid, Spain
来源
关键词
Coronary artery disease; Myocardial perfusion; Regadenoson; Perfusion cardiac magnetic resonance; Drug safety; CORONARY-ARTERY-DISEASE; HEART-RATE RESPONSE; DIAGNOSTIC PERFORMANCE; A(2A) AGONIST; DOUBLE-BLIND; ADENOSINE; TRIAL; TOLERABILITY; TOLERANCE; MR;
D O I
10.1007/s10554-023-02877-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p < 0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p < 0.001), obese (31.7%, IQR: 20.7?46.2 p = 0.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p < 0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance.
引用
收藏
页码:1765 / 1774
页数:10
相关论文
共 50 条
  • [21] Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
    Roczniak, Jan
    Baczalska, Justyna
    Kanclerz, Gabriela
    Zielinska, Weronika
    Ozga, Joanna
    Cymerman, Blazej
    Stepien, Agnieszka
    Kostkiewicz, Magdalena
    Holcman, Katarzyna
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2023, 32 (02) : 131 - 137
  • [23] Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation
    Bieging, Erik T.
    Haider, I.
    Adluru, G.
    Chang, L.
    Suksaranjit, P.
    Likhite, D.
    Shaaban, A.
    Jensen, L.
    Wilson, B. D.
    McGann, C. J.
    DiBella, E.
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2017, 33 (11): : 1781 - 1788
  • [24] Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation
    Erik T. Bieging
    I. Haider
    G. Adluru
    L. Chang
    P. Suksaranjit
    D. Likhite
    A. Shaaban
    L. Jensen
    B. D. Wilson
    C. J. McGann
    E. DiBella
    The International Journal of Cardiovascular Imaging, 2017, 33 : 1781 - 1788
  • [25] Regadenoson safety and tolerability in myocardial perfusion imaging
    Catalano, M.
    Annunziata, G.
    Sasso, A.
    Gottilla, R.
    Scala, D.
    Ippolito, V.
    Valenti, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S516 - S516
  • [26] Feasibility and prognostic value of vasodilator stress perfusion CMR in patients with atrial fibrillation
    Pezel, T.
    Sanguineti, F.
    Kinnel, M.
    Bonnet, G.
    Landon, V
    Hovasse, T.
    Garot, P.
    Unterseeh, T.
    Champagne, S.
    Louvard, Y.
    Morice, M. G.
    Garot, J.
    EUROPEAN HEART JOURNAL, 2020, 41 : 251 - 251
  • [27] Feasibility and Prognostic Value of Vasodilator Stress Perfusion CMR in Patients With Atrial Fibrillation
    Pezel, Theo
    Sanguineti, Francesca
    Kinnel, Marine
    Landon, Valentin
    Toupin, Solenn
    Unterseeh, Thierry
    Louvard, Yves
    Champagne, Stephane
    Morice, Marie Claude
    Hovasse, Thomas
    Garot, Philippe
    Garot, Jerome
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (02) : 379 - 389
  • [28] Tolerance, hemodynamic changes, and safety of dobutamine stress perfusion imaging
    Dakik, HA
    Vempathy, H
    Verani, MS
    JOURNAL OF NUCLEAR CARDIOLOGY, 1996, 3 (05) : 410 - 414
  • [29] LV wall motion assessment during regadenoson vasodilator stress CMR
    Michael Jesinger
    Vincent L Sorrell
    Steve W Leung
    Journal of Cardiovascular Magnetic Resonance, 18 (Suppl 1)
  • [30] Diagnostic performance of regadenoson stress CMR for detection of coronary artery disease
    Mita Patel
    Victor Mor-Avi
    Sandeep Nathan
    Roberto Lang
    Amit R Patel
    Journal of Cardiovascular Magnetic Resonance, 17 (Suppl 1)